Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

被引:84
作者
Broeker, Michael [1 ]
Dull, Peter M. [2 ]
Rappuoli, Rino [3 ]
Costantino, Paolo [3 ]
机构
[1] Novartis Vaccines & Diagnost GmbH & Co KG, D-35041 Marburg, Germany
[2] Novartis Vaccines & Diagnost Inc, Cambridge, MA USA
[3] Novartis Vaccines & Diagnost Srl, Siena, Italy
关键词
Conjugate vaccine; Meningococcal disease; Formulation; C POLYSACCHARIDE VACCINE; IMMUNOLOGICAL MEMORY; HUMAN IMMUNITY; GROUP-A; CAPSULAR POLYSACCHARIDE; GLYCOCONJUGATE VACCINE; ANTIBODY-RESPONSE; CHAIN-LENGTH; GROUP-B; INFANTS;
D O I
10.1016/j.vaccine.2009.07.036
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Meningococcal disease is a serious medical condition that can prove fatal within hours in otherwise healthy individuals. Disease incidence is highest in infants, yet there is no broadly protective quadrivalent vaccine that covers this age group. Anew investigational quadrivalent meningococcal glycoconjugate vaccine against meningococcal serogroups A, C, W-135, and Y (MenACVVY-CRM, Novartis Vaccines, Siena, Italy), has been developed to meet this medical need. This article discusses the vaccine technology behind MenACWY-CRM, focusing on the heritage of CRM197, the conjugation chemistry, the sizing of the oligosaccharides, and the advantages that these may confer on the vaccine. We highlight the differences between available vaccines and look at the clinical experience with vaccines against other diseases, demonstrating the importance of each component to the immunogenicity of conjugate vaccines. The specific technological approach, including conjugation of meningococcal oligosaccharides of defined length to the CRM197 protein, has led to a vaccine that has the potential to provide broad meningococcal protection against serogroups A, C, W-135, and Y for all ages. (c) 2009 Published by Elsevier Ltd.
引用
收藏
页码:5574 / 5580
页数:7
相关论文
共 66 条
[1]   DECLINE OF CHILDHOOD HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN THE HIB VACCINE ERA [J].
ADAMS, WG ;
DEAVER, KA ;
COCHI, SL ;
PLIKAYTIS, BD ;
ZELL, ER ;
BROOME, CV ;
WENGER, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02) :221-226
[2]   Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age [J].
AlMazrou, Y ;
Khalil, M ;
Borrow, R ;
Balmer, P ;
Bramwell, J ;
Lal, G ;
Andrews, N ;
AlJeffri, M .
INFECTION AND IMMUNITY, 2005, 73 (05) :2932-2939
[3]  
ANDERSON PW, 1989, J IMMUNOL, V142, P2464
[4]  
ANDERSON PW, 1986, J IMMUNOL, V137, P1181
[5]  
Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P794
[6]  
[Anonymous], 2009, MMWR Morb Mortal Wkly Rep, V57
[7]   Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135 [J].
Bardotti, A ;
Averani, G ;
Berti, F ;
Berti, S ;
Galli, C ;
Giannini, S ;
Fabbri, B ;
Proietti, D ;
Ravenscroft, N ;
Ricci, S .
VACCINE, 2005, 23 (16) :1887-1899
[8]   Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases [J].
Bardotti, Angela ;
Averani, Giovanni ;
Berti, Francesco ;
Berti, Stefania ;
Carinci, Valeria ;
D'Ascenzi, Sandro ;
Fabbri, Barbara ;
Glannini, Sara ;
Giannozzi, Aldo ;
Magagnoli, Claudia ;
Proietti, Daniela ;
Norelli, Francesco ;
Rappuoli, Rino ;
Ricci, Stefano ;
Costantino, Paolo .
VACCINE, 2008, 26 (18) :2284-2296
[9]   Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM197 conjugates induce protection against Streptococcus pneumoniae type 3 in mice [J].
Benaissa-Trouw, B ;
Lefeber, DJ ;
Kamerling, JP ;
Vliegenthart, JFG ;
Kraaijeveld, K ;
Snippe, H .
INFECTION AND IMMUNITY, 2001, 69 (07) :4698-4701
[10]   Use of meningococcal vaccines in the United States [J].
Bilukha, Oleg ;
Messonnier, Nancy ;
Fischer, Marc .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) :371-376